Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943026 | 0.92 | ITGB2 (0.41) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL3939139 | 0.90 | ITGB2 (0.41) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL4632690 | 0.89 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL4633717 | 0.89 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL3944155 | 0.87 | ROCK2 (0.38) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL13911141 | 0.87 | ROCK2 (0.38) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL3941491 | 0.87 | ROCK2 (0.38) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL13911177 | 0.87 | ROCK2 (0.38) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL14069746 | 0.87 | ITGB2 (0.40) | ROCK2ROCK1HDAC3HDAC1HDAC2 | |
| SCHEMBL4633716 | 0.87 | ITGB2 (0.40) | ROCK2ROCK1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | claimed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | claimed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | ROCK2 2280/4885ROCK1 2120/4885HDAC3 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.